Coherus BioSciences (CHRS) Reports Q1 Loss Per Share of $1.22
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 -1.35%
Revenue Growth %: +91.8%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +91.8%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($1.22), versus ($6.03) reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
